Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis.
Removal of access to alemtuzumab for patients with aggressive multiple sclerosis.
[Cognitive disorders in multiple sclerosis: correlations between neuropsychological, neurophysiological and neuroimaging characteristics.]
Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report.
Prevalence and Impact of Pain in Adults Aging With a Physical Disability: Comparison to a US General Population Sample.
Disease modification in multiple sclerosis: an update.
IL-12, but not IL-23, induces the expression of IL-7 in microglia and macrophages: Implications for multiple sclerosis.
Comparison of the Effect of 8 weeks Aerobic and Yoga Training on Ambulatory Function, Fatigue and Mood Status in MS Patients.
Management of faecal incontinence and constipation in adults with central neurological diseases.
Activated Human CD4+CD45RO+ Memory T-Cells Indirectly Inhibit NLRP3 Inflammasome Activation through Downregulation of P2X7R Signalling.
The role of cerebellar abnormalities in neuromyelitis optica - a comparison with multiple sclerosis and healthy controls.
Distilling the essence of appraisal: a mixed methods study of people with multiple sclerosis.
Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis?
Need for the upcoming revision of the current diagnostic criteria for NMO - response to the letter from Zhou et al.
Chemokine receptor expression of T cells in the cerebrospinal fluid of relapsing multiple sclerosis.
The CD27 and CD70 Costimulatory Pathway Inhibits Effector Function of T Helper 17 Cells and Attenuates Associated Autoimmunity.
Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13.
Experimental and therapeutic opportunities for stem cells in multiple sclerosis.
Ciliary Neurotrophic Factor Role in Myelin Oligodendrocyte Glycoprotein Expression in Cuprizone-Induced Multiple Sclerosis Mice.
Correlation analysis of visual analogue scale and measures of walking ability in multiple sclerosis patients.
Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis: A Novel Magnetic Resonance Imaging Scoring System.
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis.
Gut dysfunction in patients with multiple sclerosis and the role of spinal cord involvement in the disease.
[Present and future of the transcranial magnetic stimulation].
Pages
« first
‹ previous
…
382
383
384
385
386
387
388
389
390
…
next ›
last »